Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/72407
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Quality standards and samples in genetic testing
Author: Ravine, D.
Suthers, G.
Citation: Journal of Clinical Pathology, 2012; 65(5):389-393
Publisher: British Med Journal Publ Group
Issue Date: 2012
ISSN: 0021-9746
1472-4146
Statement of
Responsibility: 
David Ravine and Graeme Suthers
Abstract: The most critical performance indicator for medical laboratories is the delivery of accurate test results. In any laboratory, there is always the possibility that random or systematic errors may occur and place human health and welfare at risk. Laboratory quality assurance programmes continue to drive improvements in analytical accuracy. The most rigorously scrutinised data on laboratory errors, which come from transfusion medicine, reveal that the incidence of analytical errors has fallen to levels where most of the residual risk is now found in preanalytical links in the chain from patient to result, particularly activities associated with ordering of tests and sample collection. This insight is important for genetic testing because, like pretransfusion testing of patients with unknown blood groups, a substantial proportion of genotyping results cannot be immediately verified. An increasing number of clinical decisions, associated personal and social choices, and legal outcomes are now influenced by genetic test results in the absence of other confirmatory data. An incorrect test result may lead to unnecessary and irreversible interventions, which may in themselves have associated risks for the patient, inaccurate risk assessment regarding the disease, missed opportunities for disease prevention or even wrongful conviction in a court of law. Unfortunately, there is limited information available about the risk of preanalytical errors associated with, and few published guidelines regarding, sample collection for genetic testing. The growing number and range of important decisions made on the basis of genetic findings warrant a reappraisal of current standards to minimise risks in genetic testing.
Keywords: Humans; Paraganglioma, Extra-Adrenal; Multiple Endocrine Neoplasia Type 2a; Genetic Predisposition to Disease; Succinate Dehydrogenase; Diagnostic Errors; Thyroidectomy; Artifacts; Risk Assessment; Reproducibility of Results; Genotype; Mutation; Adult; Quality Assurance, Health Care; Male; Proto-Oncogene Proteins c-ret; Genetic Testing; Medical Laboratory Science
Rights: Copyright © 2012 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists. All rights reserved.
RMID: 0020118979
DOI: 10.1136/jclinpath-2011-200519
Appears in Collections:Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.